3 Growth Stocks That Could Generate 10X Returns

The article highlights three speculative long-term winners: CRISPR Therapeutics, Green Thumb Industries, and Joby Aviation. CRISPR has Casgevy approved and generated $116 million in 2025 revenue, Green Thumb posted $114 million in net income on nearly $1.2 billion of revenue, and Joby could benefit if its eVTOL air taxi wins approval. Overall tone is constructive but cautious, with the main catalyst for all three names tied to regulatory progress and future commercialization rather than near-term fundamentals.

Analysis

CRSP is the only name in the group where the market could be underestimating the slope of the revenue curve rather than just the size of the eventual market. The key second-order effect is that every incremental payer/provider rollout reduces the “science risk” discount and shifts the stock from binary trial optics to commercial execution optics, which tends to expand the valuation multiple before peak sales are visible. VRTX is the quiet economic backstop here: if Casgevy scales, the partner gets a cleaner operating narrative and can use cash flow from its base business to fund adjacent risk without stressing the balance sheet.

The more interesting contrast is JOBY versus the healthcare names. JOBY is a classic expectations trap: the equity can rerate violently on certification headlines, but the longer-term issue is not approval, it is unit economics and infrastructure utilization. Even if the aircraft works, the market may eventually punish a slow revenue ramp because fixed costs, pilot/ops training, vertiport development, and maintenance economics can overwhelm early revenue quality; that makes this a momentum trade, not a fundamental compounder, unless commercial density arrives much faster than expected.

GTBIF is the cleanest contrarian setup because the market still prices the sector as if federal reform will never translate into earnings power. The upside is not just better access to capital or interstate distribution; it is lower compliance drag, improved gross margin mix, and a larger buyer universe that can compress the sector’s cost of equity. The consensus likely misses how quickly multiple expansion can precede operating changes once federal policy turns, but the risk is that reform headlines get ahead of real dispensary economics, creating a sharp sell-the-news reaction.

Net/net, the opportunity set favors owning the highest operating leverage to policy normalization, while treating JOBY as a catalyst-driven trading instrument. The best risk/reward is in names where regulation changes convert directly into cash flow, not just sentiment. Until evidence shows JOBY can translate approval into repeatable revenue at acceptable cash burn, it deserves a valuation discount even if it remains popular with retail flows.

Key Decisions for Investors

• Long CRSP on a 6-12 month horizon into rollout milestones; add on commercial adoption data rather than approvals alone, with upside tied to multiple re-rating as recurring revenue visibility improves.
• Pair trade: long CRSP / short an unprofitable clinical-stage biotech basket over 3-6 months to isolate de-risking and commercialization optionality versus pure pipeline beta.
• Buy GTBIF on policy weakness, not headline spikes; target a 6-18 month hold for federal reform optionality, with the thesis that earnings quality and access to capital improve before full legalization.
• Trade JOBY tactically only around catalyst windows via call spreads or event-driven longs; use tight risk limits because approval can lift the stock sharply, but a delayed commercialization ramp can erase gains just as fast.
• Avoid or underweight JOBY as a long-duration investment until evidence of post-approval utilization and gross margin trajectory emerges; the risk/reward is asymmetric only if certification is followed quickly by durable demand.